267 related articles for article (PubMed ID: 9190955)
1. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.
Kaul R; Wu B; Goluszko E; Deng C; Dedhia V; Nabozny GH; David CS; Rimm IJ; Shenoy M; Haqqi TM; Christadoss P
J Immunol; 1997 Jun; 158(12):6006-12. PubMed ID: 9190955
[TBL] [Abstract][Full Text] [Related]
2. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains.
Wu B; Shenoy M; Goluszko E; Kaul R; Christadoss P
J Immunol; 1995 Apr; 154(7):3603-10. PubMed ID: 7897239
[TBL] [Abstract][Full Text] [Related]
3. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice.
Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA
J Immunol; 1992 Jun; 148(11):3385-90. PubMed ID: 1375242
[TBL] [Abstract][Full Text] [Related]
4. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
Lobito AA; Yang B; Lopes MF; Miagkov A; Adams RN; Palardy GR; Johnson MM; McFarland HI; Recher M; Drachman DB; Lenardo MJ
Eur J Immunol; 2002 Jul; 32(7):2055-67. PubMed ID: 12115627
[TBL] [Abstract][Full Text] [Related]
5. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
6. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
Atassi MZ; Oshima M
Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
[TBL] [Abstract][Full Text] [Related]
8. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
9. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis.
Kaul R; Shenoy M; Goluszko E; Christadoss P
J Immunol; 1994 Mar; 152(6):3152-7. PubMed ID: 8144909
[TBL] [Abstract][Full Text] [Related]
11. C5 gene influences the development of murine myasthenia gravis.
Christadoss P
J Immunol; 1988 Apr; 140(8):2589-92. PubMed ID: 3356901
[TBL] [Abstract][Full Text] [Related]
12. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
13. T cell receptor expression and differential proliferative responses by T cells specific to a myasthenogenic peptide.
Kirshner SL; Waisman A; Zisman E; Ben-Nun A; Mozes E
Cell Immunol; 1997 Aug; 180(1):20-8. PubMed ID: 9316635
[TBL] [Abstract][Full Text] [Related]
14. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
15. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis.
Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M
J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019
[TBL] [Abstract][Full Text] [Related]
16. Endogenous CD4+BV8S2- T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG-/- mice.
Matejuk A; Buenafe AC; Dwyer J; Ito A; Silverman M; Zamora A; Subramanian S; Vandenbark AA; Offner H
J Neurosci Res; 2003 Jan; 71(1):89-103. PubMed ID: 12478617
[TBL] [Abstract][Full Text] [Related]
17. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
18. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors.
Bellone M; Ostlie N; Lei S; Conti-Tronconi BM
Eur J Immunol; 1991 Oct; 21(10):2303-10. PubMed ID: 1680694
[TBL] [Abstract][Full Text] [Related]
19. Plasticity of the T cell receptor repertoire in TCR beta-chain transgenic mice.
Listman JA; Rimm IJ; Wang Y; Geller MC; Tang JC; Ho S; Finn PW; Perkins DL
Cell Immunol; 1996 Jan; 167(1):44-55. PubMed ID: 8548844
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
Shi FD; Li H; Wang H; Bai X; van der Meide PH; Link H; Ljunggren HG
J Immunol; 1999 May; 162(10):5757-63. PubMed ID: 10229808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
